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Abstract
Aims The diagnostic value of natriuretic peptides in
asymptomatic patients at risk for diastolic or systolic HF is
controversial. We tested (1) the prevalence of preclinical
LV dysfunction in an at-risk cohort; (2) the diagnostic
accuracy of natriuretic peptides alone or in combination
with clinical parameters for predicting asymptomatic left
ventricular systolic or diastolic dysfunction.
Methods 542 primary care patients (mean age 63 ±
11 years, 42% female) without prediagnosed HF, but with
risk factors for left ventricular dysfunction, underwent
thorough cardiological workup, including echocardiogra-
phy and analysis of natriuretic peptides.
Results 23 patients (4%) showed reduced systolic function
(EF\50%), and 15 patients (3%) had severe diastolic
dysfunction. All natriuretic peptides signiﬁcantly increased
with decreasing ejection fraction and with increasing degree
of diastolic dysfunction. For natriuretic peptides, receiver
operating characteristics analysis yielded good results for
the detection of systolic dysfunction or severe diastolic
dysfunction. Combining clinical parameters with natriuretic
peptide data improved the diagnostic accuracy and largely
reduced the number of needed screening echoes to identify
patients with LV systolic or diastolic dysfunction.
Conclusions The prevalence of preclinical diastolic dys-
function is high in primary care patients at risk, but the
relative prevalence of severe diastolic dysfunction and
systolic dysfunction is only 7%. High-risk individuals may
be screened most efﬁciently by using a score system
incorporating clinical data and NT-proBNP.
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Introduction
Systolic and diastolic heart failure (HF) are common and
costly diseases and represent the most common discharge
diagnosis for hospitalised patients in the United States and
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DOI 10.1007/s00392-009-0108-zEurope [20]. HF is one of the leading causes of morbidity
and mortality and a progressive disease often resulting
from clinically unapparent forms of ventricular dysfunc-
tion. Recent guidelines have suggested novel deﬁnitions for
staging HF that now include patients at risk or with pre-
clinical left ventricular dysfunction (stages A and B of the
AHA/ACC HF classiﬁcation), which are believed to be
precursors of symptomatic HF [3, 29].
Systolic dysfunction has been found to be associated
with an increased risk to develop symptomatic systolic HF.
About 50% of individuals with left ventricular systolic
dysfunction remain undiagnosed and untreated, although
early therapy may improve outcome [1].
Diastolic dysfunction is believed to be a precursor of
diastolic HF, but the impact of early therapy on the risk to
develop symptomatic HF is less well deﬁned. Treatment of
hypertension may improve diastolic function, and this gives
advice to aggressively treat diastolic dysfunction [33].
New strategies, needed to identify and treat patients with
or at risk for the development of congestive HF in a more
cost-effective way, may include early treatment of pre-
clinical stages of HF (stage B) to prevent or delay the
progression to symptomatic HF stages C and D.
Considering the large number of patients at risk for or
with asymptomatic left ventricular dysfunction, interest is
growing in the use of natriuretic peptides as diagnostic
markers of altered left ventricular structure and function [5].
As an increase in left atrial pressure is a hallmark in
moderate and severe diastolic dysfunction and the natri-
uretic peptide NT-proANP is predominantly secreted by
the left atrium, the ratio of NT-proANP to NT-proBNP
may be useful in identifying patients with severe diastolic
dysfunction [8, 10, 15, 21, 23].
The aim of the present study was to test the diagnostic
value of natriuretic peptides in identifying patients with
preclinical, asymptomatic systolic or diastolic dysfunction.
Moreover, we analysed the value of the NT-proANP/NT-
proBNP ratio. In addition, the efﬁcacy of different
screening models based on plasma levels of natriuretic
peptides, clinical information or both for the detection of
preclinical ventricular dysfunction was analysed.
Methods
Study population
Between January 2003 and June 2004, 2,273 primary care
patients from 58 practices in the city of Goettingen and
surrounding communities were invited by their general
practitioners to participate in the study. Inclusion criteria
were the presence of at least one cardiovascular risk factor
documented by the general practitioner (hypertension,
diabetes, family history of coronary artery disease) or
coronary artery disease. Patients were invited to participate
by a leaﬂet informing about the study and a total of 542
came for the study [19]. Patients were included if they had
been diagnosed to be hypertensive by their treating phy-
sician or if they were on antihypertensive therapy. Patients
were classiﬁed as diabetic if this diagnosis was made by
their treating physician or if they were on antihyperglyce-
mic therapy. Coronary artery disease (CAD) was deﬁned as
angiographic evidence of CAD, a history of revasculari-
zation or a history of myocardial infarction [34]. All par-
ticipants were clinically evaluated by trained cardiologists.
The study complies with the Declaration of Helsinki and
was approved by the local Ethics committee. All patients
gave written informed consent.
Echocardiography
Echocardiography was performed by trained cardiologists
using a Philips Sonos Agilent 5500 system (3.5 MHz
transducer) according to standard techniques as deﬁned by
the American Society of Echocardiography [4]. An ejection
fraction (EF)\50%, determined by Simpson’s monoplane
method, was deﬁned as systolic dysfunction. None of the
patients had signiﬁcant primary valvular disease. Patients
with normal systolic function (EF C 50%) were stratiﬁed
according to diastolic function [27]. Transmitral left ven-
tricularﬁllingvelocitiesatthetipsofthemitralvalveleaﬂets
as well as E wave deceleration time (EDCT) were obtained.
Isovolumetric relaxation time (IVRT) was obtained in the
apical ﬁve-chamber view. Pulmonary venous ﬂow signals
wererecordedintherightupperpulmonaryveinandtheratio
ofsystolic todiastolicvelocity (S/D) wasanalysed.Velocity
ﬂow propagation (Vp) was measured by colour Doppler
M-mode in the middle of the mitral valve.
Doppler tissue imaging was used to derive early (Ea)
and late (Aa) diastolic velocities at the septal margin of the
mitral annulus.
Diastolic dysfunction was classiﬁed as follows: nor-
mal diastolic function (1\E/A\2, 150 ms\EDCT\
280 ms, IVRT\105 ms, S/D[1, Ea[8 cm/s, Vp[
45 cm/s), mild diastolic dysfunction (E/A\1, EDCT[
280 ms, IVRT[105 ms, S/D[1, Ea\8 cm/s, Vp\
45 cm/s), moderate diastolic dysfunction (1\E/A\2,
150 ms\EDCT\200 ms, 60 ms\IVRT\105 ms,
S/D\1, Ea\8 cm/s, Vp\45 cm/s). For severe dia-
stolic dysfunction, a restrictive ﬁlling pattern (E/A[2) or
echocardiographic signs of diastolic dysfunction in com-
bination with two signs of elevated ﬁlling pressures were
required: E/Ea[15 and left atrial diameter[45 mm (for
summary see Table 1)[ 24, 25, 32]. One of the authors
(SK), blinded to all other clinical data, categorised all
patients into the stage of diastolic function. Any diastolic
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123dysfunction summarises all groups from mild to severe
diastolic dysfunction.
Analysis of natriuretic peptides: NT-proANP, BNP,
NT-proBNP
Blood was drawn under standardised conditions after a 30-
min supine rest on the same day as with the echocardio-
gram. NT-proANP was measured using a sandwich enzyme
immunoassay (Immundiagnostik, Bensheim, Germany)
and a Milenia microtiter plate reader. NT-proBNP and
BNP were determined by means of a sandwich chemilu-
minescence immunoassay on an Elecsys 2010
 analyzer
(Roche Diagnostics, Mannheim, Germany) and a Centaur
(Bayer Vital, Leverkusen, Germany), respectively. The
intra-assay coefﬁcient of variation for NT-proBNP was
1.8% for 221 pg/mL and 3.1% for 4,250 pg/mL; the inter-
assay coefﬁcient of variation was 5.5% for 187 pg/mL,
7.0% for 3,120 pg/mL, and 7.3% for 12,376 pg/mL. All
measurements were performed in duplicate in a blinded
manner by the certiﬁed core lab according to the recom-
mendations of the manufacturer.
Statistical analysis
Data were analysed using SAS 9.1 software (SAS Institute
Inc., Cary, NC, USA) and MedCalc10.0 (MedCalc Soft-
ware, Mariakerke, Belgium).
Clinical parameters are expressed as mean ± standard
deviations. Natriuretic peptide plasma levels were log-
transformed to get a normal distribution and were reported
as median values [25 percentile–75 percentile]. Differences
of normally distributed variables were compared using
analysis of variance (ANOVA), whereby the p-values
reported were adjusted for multiplicity by using Bonfer-
roni’s method.
For differences of non-normally distributed variables,
Mann–Whitney’s U test was used. Effects of covariates
were assessed by multivariate stepwise logistic analysis.
All serial parameters have been tested for normal distri-
bution. If data were found not to be normally distributed, a
log-transformation was performed.
The ability of various parameters to detect left ventric-
ular dysfunction was analysed by using the receiver-oper-
ating characteristic (ROC) curve. The optimal cut-off for
each end point was chosen by the Youden criterion [35].
The developed score was validated by leave-one-out cross
validation. This procedure involves using a single obser-
vation from the original sample as the validation data and
the remaining observations as the training data. This is
repeated such that each observation in the sample is used
once as the validation data [14, 18]. A p-value less than
0.05 was considered as statistic signiﬁcance.
Results
Clinical and echocardiographic characteristics
of the study population
For this study 542 patients were prospectively recruited
(for details see Table 2). 23 patients (4%) had a de novo
diagnosis of reduced EF (\50%). 352 patients (65%)
demonstrated echocardiographic signs of isolated diastolic
dysfunction (292 mild, 45 moderate, 15 severe).
Natriuretic peptides as predictors of left ventricular
function
Natriuretic peptides were lowest in participants with nor-
mal systolic and diastolic functions. Plasma levels contin-
uously increased with increasing severity of left ventricular
dysfunction (Fig. 1).
Since diastolic dysfunction results in impaired left atrial
emptying with increases in left atrial wall tension, we
hypothesised that the ratio of NT-proBNP (released mainly
from the ventricles) to NT-proANP (which is released
predominantly from the atria) may be a better diagnostic
Table 1 Classiﬁcation of diastolic dysfunction
Normal function Mild diastolic dysfunction Moderate diastolic dysfunction Severe diastolic dysfunction
1\E/A\2 E/A\11 \E/A\2 E/A[2
150 ms\EDCT\280 ms EDCT[280 ms 150 ms\EDCT\200 ms –
IVRT\105 ms IVRT[105 ms 60 ms\IVRT\105 ms –
S/D[1 S/D[1 S/D\1–
Ea[8 cm/s Ea\8 cm/s Ea\8 cm/s –
Vp[45 cm/s Vp\45 cm/s Vp\45 cm/s –
LA diameter – – [45 mm
E/Ea – – [15
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123parameter for the detection of diastolic dysfunction than
each peptide alone. The NT-proBNP/NT-proANP ratio was
highest in patients with severe diastolic dysfunction and
systolic dysfunction (p\0.0001 vs. normal function).
However, there was no apparent difference in the increase
of the ratio as compared with NT-proBNP alone.
Analysis of ROC curves
For detecting preclinical systolic dysfunction (Fig. 2, upper
left panel), test characteristics were good for all three
natriuretic peptides (AUC 0.751–0.831). NT-proBNP was
the best diagnostic marker with borderline signiﬁcant dif-
ferences to NTproANP (p = 0.054) and BNP (p = 0.048).
Test characteristics of natriuretic peptides performed rather
poor in detecting any diastolic dysfunction.
Figure 2, upper right panel shows the test characteristics
for the detection of severe diastolic dysfunction by natri-
uretic peptides. Diagnostic accuracies of NT-proANP, NT-
proBNP and BNP and the ratio of NT-proBNP/NT-proANP
were all in a high range (AUC = 0.729–0.762, respec-
tively; p = 0.900–0.940).
Figure 2 (lower right panel) and Table 3 demonstrate
that all natriuretic peptides showed good test characteristics
for the detection of any ventricular dysfunction (EF\50%
or severe diastolic dysfunction). Direct comparison of the
natriuretic peptides revealed that the overall diagnostic
performance of NT-proBNP seemed to perform best in
detecting any preclinical ventricular dysfunction (AUC
0.813), but this difference failed to reach signiﬁcance
(p = 0.167 to NT-proANP, p = 0.086 to BNP).
Table 4 demonstrates that in contrast to NT-proBNP
obesity, renal insufﬁciency and age have only modest
inﬂuence on the score with respect to the AUCs for systolic
or severe diastolic dysfunction.
Table 2 Patient characteristics
Patient characteristics All
n = 542
Age (mean ± SD) 63 ± 11
Male sex (%) 58
Hypertension (%) 86
Diabetes (%) 31
Coronary artery disease (%) 30
Smoking (py) 14 ± 19
Body mass index (kg/m
2)2 9 ± 5
Septal thickness (mm) 12 ± 2
Posterior wall thickness (mm) 11 ± 2
Left ventricular mass (g).
Median [25–75 percentile]
234 [194–276]
LVEDD (mm) 51 ± 5
LA (mm) 41 ± 6
EF (%) 60 ± 8
Diastolic dysfunction (%) 71
GFR (mL/min) 82 ± 18
lnNT-proANP (pg/ml)
N vs. SD 0.0041
+ vs. SD 0.0004
lnNT-proBNP (pg/ml) lnBNP (pg/ml)
7
8
9
N vs. +++ 0.0405
+ vs. +++ 0.0095
N vs. ++ 0.01430
N vs.SD <0.0001
+ vs.SD <0.0001
++ vs.SD <0.0001
N vs.SD <0.0001
+ vs.SD <0.0001
4
5
6
N vs. +++ <0.0001
0 0002
N vs.++ 0.0063
++ vs.SD 0.0106
N + ++ +++ SD
2
3
N + ++ +++ SD
N vs. + 0.0363
+ vs. +++ 0.0002
++ vs. +++ 0.0304
N + ++ +++ SD
N vs.+++ <0.0001
+ vs.+++ 0.0008
Normal ventricular function N
D D D D DD
Mild diastolic dysfunction
Moderate diastolic dysfunction
Severe diastolic dysfunction
Systolic dysfunction (EF<50%)
+
+ +
+ + +
SD
DD
Fig. 1 Natriuretic peptides and diastolic function. Concentrations
(ordinate) of lnNT-proANP (left), lnNT-proBNP (middle) and lnBNP
(right) stratiﬁed by left ventricular diastolic function (normal (N) vs.
mild (DD?), moderate (DD??) or severe (DD???) diastolic
dysfunction; abscissa). Values for systolic dysfunction (SD;
EF\50%) are given for comparison. Boxes deﬁne the interquartile
range with the median indicated by the crossbar. Error bars indicate
the 10th and 90th percentiles
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123Multivariate regression analysis and testing
of a multivariable scoring system
To optimise the detection of patients with preclinical
ventricular dysfunction, we performed univariate and
multivariate regression analysis using the following vari-
ables: lnNT-proBNP, age, hypertension, diabetes, CAD,
and dyspnea on exertion. Variables were taken into the
model if p\0.05 and were not taken out if p\0.10.
LnNT-proBNP and dyspnea on exertion were indepen-
dently associated with systolic dysfunction and lnNT-
proBNP, diabetes, dyspnea on exertion, hypertension and
CAD were independent predictors of severe preclinical
diastolic dysfunction.
ForsystolicorseverediastolicdysfunctionlnNT-proBNP,
hypertension, diabetes, CAD and dyspnea on exertion were
independent predictors. From these parameters, we derived a
score system that incorporated, besides lnNT-proBNP, those
clinical variables with the best prediction characteristics for
asymptomatic left ventricular dysfunction. The score was
calculated (with regression coefﬁcients of covariates) as
follows: Scoreventricular dysfunction NT-proBNP = 1.054 9 diabe-
tes (0 = no, 1 = yes) ? 1.884 9 hypertension ? 1.199 9
dyspnea on exertion ? 0.970 9 coronary artery dis-
ease ? 1.003 9 lnNT-proBNP.
For comparison, we also calculated a score with
the aforementioned clinical variables, but without
NT-proBNP. Scoreventricular dysfunction clinical = 0.935 9
diabetes ? 2.256 hypertension ? 1.320 9 dyspnea on
exertion ? 1.489 9 coronary artery disease.
We next tested the diagnostic accuracy of the score as
compared with lnNT-proBNP alone and the score with
NT-proBNPascomparedwiththescorewithoutNT-proBNP
in ROC analyses (Fig. 2; Table 3). The score that combines
clinical parameters with lnNT-proBNP was of signiﬁcantly
better diagnostic accuracy than lnNT-proBNP alone in
detectingsystolicorseverediastolicdysfunction(p = 0.02).
Moreover, the score incorporating NT-proBNP showed a
signiﬁcantly better diagnostic performance compared with
thesoleclinicalscore(withoutNT-proBNP)forthediagnosis
of a systolic or severe diastolic dysfunction (p = 0.032).
Validation of this new score by ‘‘leave one out’’-cross
validation revealed a percentage of correctly speciﬁed indi-
viduals of 95% for systolic dysfunction, 93% for systolic or
severe diastolic dysfunction and 96% for severe diastolic
dysfunction, but only of 35% for any diastolic dysfunction.
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Fig. 2 ROC analysis of
natriuretic peptides and the
score in the diagnosis of any
systolic (EF[50%; upper left),
severe diastolic (upper right)
and systolic or severe diastolic
(lower right) dysfunction. AUC
values and statistical analysis is
summarised in Table 2
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123Table 3 AUCs for systolic and/or severe diastolic dysfunction
Variable AUC [CI] Cut-off Sensitivity Speciﬁcity Negative
predictive
value
Positive
predictive
value
p vs. Score
(with NT-
proBNP)
Systolic dysfunction
LnNTproANP (pg/mL) 0.751 [0.636–0.866] 8.45 (4,675.07) 65 81 98 13
LnNTproBNP (pg/mL) 0.831 [0.748–0.914] 5.94 (379.93) 65 88 98 19
LnBNP (pg/mL) 0.769 [0.651–0.886] 4.65 (104.59) 61 90 98 22
QlnNBNP/lnNANP 0.835 [0.759–0.910] 0.70 70 86 98 18
Age 0.692 [0.594–0.791] 67 65 66 98 8
Score (with NT-proBNP) 0.883 [0.828–0.938] 8.13 91 71 99 12
Score (without NT-proBNP) 0.792 [0.695–0.888] 3.66 70 72 98 10
Severe diastolic dysfunction
LnNTproANP (pg/mL) 0.762 [0.647–0.878] 8.19 (3,604.72) 87 63 99 6
LnNTproBNP (pg/mL) 0.758 [0.620–0.895] 5.67 (290.03) 67 83 99 10
LnBNP (pg/mL) 0.754 [0.620–0.889] 4.06 (57.97) 73 72 99 5
QlnNBNP/lnNANP 0.729 [0.588–0.870] 0.71 60 86 98 11
Age 0.724 [0.596–0.852] 69 67 73 99 6
Score (with NT-proBNP) 0.881 [0.803–0.960] 8.13 90 73 99 11
Score (without NT-proBNP) 0.806 [0.716–0.896] 3.66 68 73 98 8
Systolic or severe distolic dysfunction
LnNTproANP (pg/mL) 0.765 [0.681–0.849] 8.25 (3,827.63) 79 68 98 16 0.004
LnNTproBNP (pg/mL) 0.813 [0.738–0.888] 5.94 (379.93) 63 89 97 30 0.022
LnBNP (pg/mL) 0.772 [0.683–0.862] 4.06 (57.97) 74 75 97 18 0.001
QlnNBNP/lnNANP 0.803 [0.729–0.877] 0.70 66 87 97 27 0.011
Age 0.712 [0.633–0.792] 69 61 74 96 15 0.001
Score (with NT-proBNP) 0.882 [0.831–0.932] 8.13 90 72 99 20
Score (without NT-proBNP) 0.805 [0.732–0.877] 3.66 68 73 97 16 0.032
Table 4 Comorbidities and AUCs for systolic or severe diastolic dysfunction
Comorbidity Variable AUC
Obesity
BMI\25 kg/m
2 Score (with NT-proBNP) 0.904 [0.816–0.992]
Score (without NT-proBNP) 0.818 [0.631–1.000]
BMI[25 kg/m
2 Score (with NT-proBNP) 0.879 [0.821–0.937]
Score (without NT-proBNP) 0.801 [0.722–0.881]
Renal insufﬁciency
Estimated glomerular ﬁltration rate[60 mL/min Score (with NT-proBNP) 0.867 [0.808–0.925]
Score (without NT-proBNP) 0.788 [0.699–0.878]
Estimated glomerular ﬁltration rate\60 mL/min Score (with NT-proBNP) 0.945 [0.888–1.000]
Score (without NT-proBNP) 0.826 [0.721–0.931]
Age
\70 years Score (with NT-proBNP) 0.898 [0.829–0.966]
Score (without NT-proBNP) 0.814 [0.709–0.918]
[70 years Score (with NT-proBNP) 0.819 [0.719–0.919]
Score (without NT-proBNP) 0.756 [0.649–0.863]
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123Optimised screening approach for asymptomatic left
ventricular dysfunction
We compared different possible screening strategies to
detect severe ventricular dysfunction (i.e., EF\50% or/
and severe diastolic dysfunction; Table 5). By deﬁnition, a
strategy that applies screening echocardiography to all
patients at risk has 100% sensitivity and speciﬁcity and a
positive likelihood ratio of 1, but the number needed to
screen for one patient positive for the diagnosis is 14.3.
Including NT-proBNP (cut-off 209.5 pg/mL) into the
diagnostic workup reduces sensitivity and speciﬁcity to 74
and 75%, respectively, but also largely reduces the number
of screening echoes needed to identify one patient with any
preclinical ventricular dysfunction to 5.5 (at the expense,
however, of 26% positives missed). The most efﬁcient
strategy (see number needed to screen) is to apply
echocardiography to all patients with diabetes and a
NT-proBNP above the cut-off level of 209.5 pg/mL. Every
third patient screened will be diagnosed to have severe
ventricular dysfunction; however, with this approach only
one-third of all patients with severe ventricular dysfunction
would be detected.
Overall test characteristics were best for the developed
screening score: using this score (cut-off set at 8.551
points), sensitivity and speciﬁcity for accurate diagnosis
were 82 and 79%, respectively; the number of screening
echoes needed to identify one affected patient was 4.5, with
only 18% of positive patients missed (Table 5). Figure 3
shows the superiority of the score system that combines
clinical and lnNT-proBNP values versus lnNT-proBNP
alone in identifying patients in need of echocardiography.
With increasing sensitivity, the score largely reduced the
number of echoes needed as compared with NT-proBNP
alone. For instance, to detect at least 80% of the affected
patients, this would necessitate echocardiography in 42%
of participants if decision was based on NT-proBNP only
as compared with 26% (relative reduction of 38%) when
using the score.
Discussion
The present study demonstrates that in patients at risk for
HF, natriuretic peptides help diagnosing systolic and severe
diastolic dysfunction. A score system that combines clini-
cal parameters with natriuretic peptide measurement pro-
vides additive diagnostic accuracy for asymptomatic
systolic or severe diastolic dysfunction.
Our study has two new ﬁndings:
1. A combination of clinical variables with natriuretic
peptides (either BNP or NT-proBNP) in a scoring
system is superior to natriuretic peptides alone and is
superior to a scoring system without NT-proBNP in
diagnosing systolic and severe diastolic dysfunctions.
Moreover, the implementation of such a score may
reduce the need for echocardiography in a primary-
care based screening programme for left ventricular
dysfunction.
2. The combination of natriuretic peptides by forming a
ratio between two (e.g. NT-proBNP and NT-proANP)
is not superior to the value of each natriuretic peptide
alone.
Role of natriuretic peptides in the detection
of ventricular dysfunction
The role of natriuretic peptides in the detection of left
ventricular systolic dysfunction is well established [13]. In
line with this and other previous observations, in our study
NT-proANP, BNP and NT-proBNP were signiﬁcantly
higher in patients with preclinical systolic dysfunction
compared with patients with normal systolic function [31].
Table 5 Different screening models
Models Sensitivity
(%)
Speciﬁcity
(%)
LR? LR– Needing NT-
proBNP (%)
Needing
Echo (%)
Disease
missed (%)
NNS by
Echo
1 Echo in all 100 100 1.0 0 0 100 0 14.3
2 NT-proBNP only, cut-off 209.5 pg/mL 74 75 2.9 0.4 100 29 26 5.5
3 Echo in all with dyspnea 71 67 2.2 0.4 0 35 29 7.1
4 If dyspnea, than NT-proBNP (cut-off
209.5 pg/mL)
53 89 4.8 0.5 35 14 47 3.8
5 Echo in all with diabetes, dyspnea or CAD 95 36 1.5 0.1 0 67 5 10.0
6 If diabetes, dyspnea or CAD, than
NT-proBNP (cut-off 209.5 pg/mL)
68 83 3.9 0.4 67 21 32 4.4
7 Score clinical (cut-off 3.66 units) 68 73 2.5 0.4 0 30 32 6.2
8 Score NT-proBNP (cut-off 8.551 units) 82 79 3.8 0.2 100 26 18 4.5
Clin Res Cardiol (2010) 99:217–226 223
123The diagnostic value of natriuretic peptides in detecting
diastolic dysfunction is by far more controversial, and
published reports showed heterogeneous results. An initial
report by Lubien et al. [22] showed very good test char-
acteristics of BNP for the detection of diastolic dysfunc-
tion. Later reports could not conﬁrm these optimistic
results. Grewal et al. could demonstrate that natriuretic
peptides were the strongest independent predictors of dia-
stolic dysfunction, as determined by Doppler-echocardi-
ography in the CHARM-Preserved trial. Of importance,
these patients suffered from HF, whereas the patients in our
study were symptom-free [11, 12, 28]. In this study, we
could demonstrate that natriuretic peptides do not accu-
rately predict mild or moderate diastolic dysfunction, but
are a very valuable tool to identify patients with severe
diastolic dysfunction. This ﬁnding is in line with those of
Costello-Boerrigter et al. and Redﬁeld et al., who found
that NT-proBNP or BNP may be useful to detect moderate/
severe diastolic dysfunction [6, 30].
One explanation for the differences between our study
and previously published studies may be that Lubien
et al. analysed a group of highly selected patients refer-
red to an echocardiographic laboratory, whereas others
chose a population-based sample [22, 28]. Due to this
referral bias, pretest probability in these studies is quite
different with signiﬁcant effects on further ﬁnal test
results. Another explanation is the deﬁnition of diastolic
dysfunction. Redﬁeld et al. [30] required two independent
echocardiographic signs of at least moderate diastolic
dysfunction to establish the diagnosis. In line with this
approach we deﬁned severe diastolic dysfunction as a
restrictive ﬁlling pattern and/or indications of elevated
ﬁlling pressure (left atrial diameter[45 mm and
E/Ea[15) [25]. An increased left atrial diameter or
volume as well as an E/Ea[15 has been associated with
elevated ﬁlling pressure in patients with HF and a normal
EF [24, 26]. Our results demonstrate that natriuretic
peptides may have a pivotal role in the screening for
severe diastolic or any systolic dysfunction in a primary
care setting.
Comparison of NT-proANP, NT-proBNP and BNP
in the detection of preclinical left ventricular
dysfunction
Our study design allowed the direct comparison of
NT-proANP, NT-proBNP and BNP in the detection of
systolic or diastolic dysfunction by either comparative
ROC analysis or comparative correlation analysis. NT-
proBNP tended to be the best marker of systolic and
severe diastolic dysfunction. However, the difference
between NT-proBNP and BNP in diagnosing diastolic and
systolic dysfunctions was not statistically signiﬁcant,
conﬁrming results from two other studies for the diag-
nosis of systolic dysfunction [6, 16].
We further hypothesised that the combination of two
markers could improve diagnostic accuracy. Since atrial
emptying into the ventricle is impaired, atrial wall stress
should be elevated in diastolic dysfunction. However, with
increasing degree of diastolic dysfunction, the NT-proBNP
to NT-proANP ratio increased, indicating that NT-proBNP
up-regulation outranges NT-proANP up-regulation in more
severe diastolic dysfunction. The NT-proBNP to NT-pro-
ANP ratio did not give additional diagnostic value as
compared with NT-proBNP alone.
These surprising results challenge the simple concept of
ANP mainly secreted by the atria and BNP mainly secreted
by the ventricles. Data from an invasive study with selec-
tive coronary sinus blood sampling showed that in atrial
ﬁbrillation, BNP is mainly secreted from the left atrium,
and not from the ventricle [17]. Thus, as all natriuretic
peptides are rather simultaneously regulated in systolic and
diastolic dysfunction, it seems more attractive to identify
the most sensitive biochemical marker.
Clinical implications
The recent deﬁnition of HF by the American Heart
Association denotes stages A-D and requires identiﬁca-
tion of patients with structural heart disease (stage B)
[3]. To evaluate the impact of natriuretic peptides as a
screening tool for patients at risk for developing HF,
three assumptions are made: (1) the prevalence of the
disease is high enough in the population studied. With an
80
60 NT-proBNP
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20
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Fig. 3 Score system in comparison to NT-proBNP alone in identi-
fying patients at risk for any systolic or severe diastolic left
ventricular dysfunction needing an echocardiogram. The number of
patients needing an echocardiogram (abscissa) is plotted versus
sensitivity of the test procedure
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and systolic dysfunction in the population studied, this
condition is fulﬁlled; (2) a therapy for these patients in
an asymptomatic stage of the disease is provided. This
holds true for systolic dysfunction as, e.g. ACE inhibi-
tors reduce progression to overt HF, but the situation is
less clear for severe diastolic dysfunction [1, 2]; (3) there
is a diagnostic test with a high sensitivity and speciﬁcity.
A screening test should have a high negative predictive
power, so that a test result below the cut-off point is
much more likely in patients without the disease. From
our results, our score system incorporating NTproBNP
provides good diagnostic accuracy, especially for systolic
or severe diastolic dysfunction. Therefore, an important
ﬁnding of our study is that the combination of spe-
ciﬁc clinical information with a point measure of NT-
proBNP improves diagnostic accuracy over each strategy
alone.
Limitations of the study
Our risk estimation model may not be ready for clinical use
because we developed and validated it in the same study
population. Validation of our model in an independent
cohort may be necessary before clinical application can be
recommended.
Parameters of electrocardiography have been previously
used to screen for diastolic dysfunction (Galasko et al. and
Goode et al.). In our study, we aimed to screen for
diastolic dysfunction without electrocardiograms. The
information given by ECG may be of incremental value
to clinical information. Therefore, in further studies
screening for diastolic dysfunction, ECG should be
included [7, 9].
Conclusion
In conclusion, the prevalence of preclinical diastolic dys-
function in a risk cohort is high, but the relative proportion
of severe diastolic dysfunction is rather low. Natriuretic
peptides are useful to detect systolic and severe diastolic
dysfunction. The additional use of clinical information
optimises a biomarker-based screening approach. Thus,
natriuretic peptides should be considered as additional
clinical information and their use in combination with other
clinical data should be considered for Public Health
screening algorithms to reduce the HF burden.
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